For Roche Immuno-Oncology, It’s Steady As She Goes
Executive Summary
Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy, illustrated in an animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq
You may also be interested in...
Roche Pushes The Boundaries Of Cancer Immunotherapy
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.
Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy
Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has reached a crucial point, with a multinational Phase III pivotal trial of Isofol’s Modufolin being cleared by regulators but funding is still needed.
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
The first round of biopharma earnings presentations reflects concerns about pricing and market access, which should carry over as big pharma stalwarts come center stage.